A detailed history of Green Alpha Advisors, LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 181,054 shares of CRBU stock, worth $277,012. This represents 0.26% of its overall portfolio holdings.

Number of Shares
181,054
Previous 103,214 75.42%
Holding current value
$277,012
Previous $201,000 42.79%
% of portfolio
0.26%
Previous 0.16%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 13, 2025

BUY
$1.59 - $2.79 $123,765 - $217,173
77,840 Added 75.42%
181,054 $287,000
Q3 2024

Oct 07, 2024

BUY
$1.56 - $2.73 $40,315 - $70,551
25,843 Added 33.4%
103,214 $201,000
Q2 2024

Aug 13, 2024

SELL
$1.62 - $5.05 $9,963 - $31,057
-6,150 Reduced 7.36%
77,371 $126,000
Q1 2024

Apr 09, 2024

BUY
$4.82 - $8.26 $19,072 - $32,684
3,957 Added 4.97%
83,521 $429,000
Q4 2023

Jan 04, 2024

SELL
$3.58 - $6.25 $110,836 - $193,500
-30,960 Reduced 28.01%
79,564 $455,000
Q3 2023

Oct 10, 2023

BUY
$4.08 - $8.14 $19,167 - $38,241
4,698 Added 4.44%
110,524 $528,000
Q2 2023

Jul 06, 2023

BUY
$4.04 - $5.47 $86,290 - $116,833
21,359 Added 25.29%
105,826 $449,000
Q1 2023

Apr 06, 2023

BUY
$4.3 - $7.78 $40,248 - $72,820
9,360 Added 12.46%
84,467 $448,000
Q4 2022

Jan 12, 2023

BUY
$5.57 - $11.01 $31,921 - $63,098
5,731 Added 8.26%
75,107 $0
Q3 2022

Oct 14, 2022

SELL
$5.34 - $12.79 $976,664 - $2.34 Million
-182,896 Reduced 72.5%
69,376 $732,000
Q2 2022

Jul 08, 2022

BUY
$5.1 - $9.74 $1.03 Million - $1.97 Million
202,598 Added 407.86%
252,272 $1.37 Million
Q1 2022

Apr 19, 2022

BUY
$8.42 - $15.32 $118,570 - $215,736
14,082 Added 39.57%
49,674 $456,000
Q4 2021

Jan 12, 2022

BUY
$14.59 - $23.26 $40,210 - $64,104
2,756 Added 8.39%
35,592 $537,000
Q3 2021

Oct 12, 2021

BUY
$15.75 - $30.29 $517,167 - $994,602
32,836 New
32,836 $784,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $93.1M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Green Alpha Advisors, LLC Portfolio

Follow Green Alpha Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.